1
Gale E Smith, Franklin Volvovitz, Bethanie E Wilkinson, Andrei I Voznesensky, Craig S Hackett: Vaccine comprising a baculovirus produced influenza hemagglutinin protein fused to a second protein. Protein Sciences Corporation, Thomas J Kowalski, Frommer Lawrence & Haug, January 12, 1999: US05858368 (82 worldwide citation)

A method of preparing a recombinant influenza vaccine using DNA technology is provided. The resulting vaccine is a multivalent, preferably trivalent, influenza vaccine based on a mixture of recombinant hemagglutinin antigens cloned from influenza viruses having epidemic potential. The recombinant he ...


2
Gale E Smith, Franklin Volvovitz, Bethanie E Wilkinson, Andrei I Voznesensky, Craig S Hackett: Method for producing influenza hemagglutinin multivalent vaccines. Protein Sciences Corporation, Thomas J Kowalski, Frommer Lawrence & Haug, June 12, 2001: US06245532 (24 worldwide citation)

A method of preparing a recombinant influenza vaccine using DNA technology is provided. The resulting vaccine is a multivalent, preferably trivalent, influenza vaccine based on a mixture of recombinant hemagglutinin antigens cloned from influenza viruses having epidemic potential. The recombinant he ...


3
Gale E Smith, Harald G Foellmer, John Knell, James DeBartolomeis, Andrei I Voznesensky: Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using. Protein Sciences Corporation, Thomas J Kowalski, Frommer Lawrence & Haug, August 15, 2000: US06103526 (18 worldwide citation)

Disclosed and claimed is a new insect cell line, Sf900+, ATCC CRL-12579. The insect cell line was established from Lepidoptera, Noctuidae, Spodoptera frugiperda Sf-9 (ATCC CRL-1771) through multiple rounds of limiting dilution and selection in a serum-free insect medium supplemented with added human ...


4
Franklin Volvovitz: Virus vaccines. Protein Sciences Corporation, Thomas J Kowalski, Frommer Lawrence & Haug, November 2, 1999: US05976552 (14 worldwide citation)

Improved mammalian virus vaccines are combinations that contain an immunogenic amount of inactivated virus, such as influenza virus, Herpes varicella virus, measles virus, Epstein Barr virus, respiratory syncytial virus, parainfluenza 3, Herpes simplex type 1 virus, and Herpes simplex type 2 virus, ...


5
Gail Eugene Smith, James T Matthews, Edwin D Kilbourne, Bert E Johansson, Bethanie E Wilkinson, Andrei I Voznesensky, Craig S Hackett, Franklin Volvovitz: Neuraminidase-supplemented compositions. Protein Sciences Corporation, William S Frommer, Thomas J Kowalski, Frommer Lawrence & Haug, November 26, 2002: US06485729 (11 worldwide citation)

An anti-influenza vaccine composition wherein the improvement is that the vaccine includes, as an additive, neuraminidase (NA). The base anti-influenza vaccine can be any commercially available anti-influenza vaccine. The composition can include and be administered with an adjuvant. The vaccine comp ...


6
Gail Eugene Smith, James T Matthews, Edwin D Kilbourne, Bert E Johansson, Bethanie E Wilkinson, Andrie I Voznesensky, Craig S Hackett, Franklin Volvovitz: Methods of making neuraminidase-supplemented compositions. Protein Sciences Corporation, Frommer Lawrence & Haug, Thomas J Kowalski, Angela M Collison, October 4, 2005: US06951649 (4 worldwide citation)

The present invention relates to a method for formulating a vaccine composition which comprises an anti-influenza vaccine, wherein the improvement of the vaccine composition is that the vaccine includes, as an additive, neuraminidase (NA). The base anti-influenza vaccine can be any commercially avai ...


7
Gale E Smith, John Knell, Andrei I Voznesensky: Apparatus and methods for producing and using high-density cells and products therefrom. Protein Sciences Corporation, Vedder Price P C, Thomas J Kowalski, Deborah L Lu, February 1, 2011: US07879601 (1 worldwide citation)

Disclosed and claimed is apparatus and methods for the growth of cells to high density, products therefrom and uses thereof. Also disclosed and claimed is the use of this method for the growth to high-density insect cells, such as the Spodoptera frugiperda Sf900+ cell line (ATCC: CRL 12579). Further ...


8
Gale E Smith, John Knell, Andrei I Voznesensky: Apparatus and methods for producing and using high-density cells and products therefrom. Protein Sciences Corporation, Frommer Lawrence & Haug, Thomas J Kowalski, Heather DiPietrantonio, October 6, 2009: US07598075 (1 worldwide citation)

Disclosed and claimed is apparatus and methods for the growth of cells to high density, products therefrom and uses thereof. Also disclosed and claimed is the use of this method for the growth to high-density insect cells, such as the Spodoptera frugiperda Sf900+ cell line (ATCC: CRL 12579). Further ...


9
D Karl Anderson, Kathleen M Holtz Corris, Rick Chubet, Daniel Adams, Manon Cox: Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using. Protein Sciences Corporation, Vedder Price P C, Thomas J Kowalski, Deborah L Lu, September 24, 2013: US08541003

SARS (severe acute respiratory syndrome virus, a coronavirus) immunogens, antigens, or epitopes, nucleic acid molecules encoding such immunogens, antigens, or epitopes; vectors containing such nucleic acid molecules, e.g., viral vectors such as baculovirus vectors, DNA vectors, such as DNA plasmid v ...


10
Gale E Smith, John Knell, Andrei I Voznesensky: In vivo active erythropoietin produced in insect cells. Protein Sciences Corporation, Thomas J Kowalski, Deborah L Lu, Vedder Price PC, September 27, 2011: US08026096

Disclosed and claimed is a human erythropoietin (EPO) expressed and produced in Spodoptera frugiperda Sf900+ cell line (ATCC: CRL 12579) transfected with a baculovirus construct containing the EPO gene. The EPO has an in vivo activity of 200,000 U/mg to 500,000 U/mg.



Click the thumbnails below to visualize the patent trend.